Report: Annual CPV Report

This is a ready-to-use annual CPV report. It is the document that states, in writing, whether a commercial process remained in a state of control for the reporting period, so present actual values and actual conclusions, not blanket statements of “acceptable.” Replace every <<FILL: ...>> placeholder with your own specifics and route it through document control. A worked filled specimen follows. Verify each cited regulation against the current source before you rely on it. This is general guidance to adapt, not legal or regulatory advice.

Approval page

1. Scope and period

Product <<FILL: PRODUCT>>, strength(s) <<FILL>>, manufactured at <<FILL: site(s)>>. Reporting period <<FILL: dates>>. This report covers <<FILL: N>> batches manufactured in the period, batch numbers <<FILL: range or list>>. Relationship to the Annual Product Review / Product Quality Review: <<FILL: this report is standalone and referenced from the APR/PQR, or this report is integrated into the APR/PQR as section X>>.

2. Batches included and exclusions

Every exclusion above must be traceable to a deviation or documented event. No batch is excluded to improve the appearance of a chart.

3. Parameters reviewed

Complete one row per monitored parameter. Attach the actual chart image or export as a report appendix; this table is the index and the narrative conclusion, not a substitute for the chart itself.

No monitored parameter from the product CPV plan is silently absent from this table. If a parameter was dropped or added during the period, state it here and cross-reference the plan revision that authorized the change.

4. Signals detected and their disposition

Every signal listed in section 3 appears here with a disposition. A chart showing a visible trend with no corresponding row in this table is treated as an unresolved finding, not an oversight to fix later.

5. Capability indices and year-over-year trend

Report both Cpk and Ppk. A parameter where Cpk is stable but Ppk is declining indicates the batch-to-batch mean is moving even though within-batch variation looks fine, and that combination is itself worth a narrative even without a formal signal.

6. Limit recalculations performed during the period

State explicitly whether any recalculation was preceded by, or coincided with, an open signal on that parameter, and if so, document the independent basis for the recalculation that would have applied regardless of the signal.

7. Process changes during the period

List validated process changes implemented during the reporting period and their assessed impact on the monitoring program: <<FILL: change control reference, description, and monitoring impact, or "no process changes this period">>.

8. Conclusion on state of control

State the explicit conclusion, supported by the data shown above, not merely asserted:

<<FILL: "The process for [PRODUCT] remained in a state of control during the reporting period. All monitored parameters showed no unresolved signals, capability indices remained at or above the target of [X], and all raised signals were investigated and closed with documented dispositions." OR describe the specific parameters and open items that prevent this conclusion, and the interim controls in place.>>

9. Recommendations and actions

Carry forward and close out last period’s recommendations here; state explicitly whether any recommendation is repeated from the prior report and why it was not closed.

10. Approvals

Acceptance criteria

A report is acceptable when all of the following are true:

• Every parameter in the current product CPV plan appears in section 3, with a chart and a stated conclusion; nothing is silently dropped.
• Every signal identified from the charts has a corresponding row and a closed or actively tracked disposition in section 4.
• The state-of-control conclusion in section 8 is supported by the data presented, not asserted independently of it.
• All exclusions in section 2 are justified and traceable, and none flatter the conclusion.
• Prior-period recommendations are shown closed, or their carry-forward is explained; a report repeating the same open recommendation three periods running triggers escalation.

References

FDA, Process Validation: General Principles and Practices (January 2011), Stage 3. 21 CFR 211.180(e), annual review of records to evaluate quality standards. EudraLex Volume 4, Annex 15, Qualification and Validation (ongoing process verification). ICH Q10, Pharmaceutical Quality System (management review, continual improvement).

Confirm the current version and clause numbers of each reference before issue.

Filled specimen

An illustrative example for a monoclonal antibody drug substance’s second year of commercial CPV.

Batches: 42 batches manufactured, 41 included, 1 excluded (batch 178, rejected at release for an unrelated container closure defect, DEV-2026-0311).

Parameters reviewed (excerpt):

Signal disposition: the Rule 3 trend on final protein concentration (documented in the linked worked example) was traced to a chromatography resin approaching end of life. CAPA CAPA-2026-0087 tightened the resin-lifetime replacement trigger from 60 to 45 cycles. Closed 15 August 2026.

Capability: final protein concentration Cpk 1.61 (prior year 1.58), Ppk 1.44 (prior year 1.52, declining, attributed to the resin-driven shift, expected to recover following the CAPA and limit recalculation).

Limit recalculation: final protein concentration limits recalculated in August 2026 using the full 50-batch data set spanning PPQ plus Stage 3a plus the first year of Stage 3b, following the trigger defined in the product CPV plan for reaching 50 accumulated batches, independent of the resin signal. Change control CC-2026-0142.

Conclusion on state of control: The process for Illustrative mAb Drug Substance, 50 mg/mL, remained in a state of control during the reporting period. One process signal was detected, investigated, and closed with an assignable cause and an effective CAPA. Capability indices remain above the internal target of 1.33. No parameter shows an unresolved trend at report date.

Recommendations: continue standard Stage 3b monitoring; re-evaluate host cell protein monitoring frequency at next annual review given 24 consecutive in-control batches with wide margin to specification (owner: MSAT, target Q1 2027).

Common inspection findings this report prevents

• A report concludes “state of control maintained” over charts that visibly show an unaddressed trend.
• A monitored parameter from the CPV plan does not appear anywhere in the annual report, with no explanation.
• Signals appear on a chart with no corresponding investigation or CAPA reference anywhere in the report.
• Limit recalculations happen with no independent basis stated, immediately following a signal, with no explanation of the timing.
• The same recommendation is repeated year after year with no evidence it was ever actioned.
• Cpk is reported while Ppk is omitted, hiding a batch-to-batch mean shift behind a within-batch capability number.

How to adapt this report

1. Set the report number, product, site, and reporting period in the approval page.
2. Populate section 3 with every parameter currently in your product CPV plan, and attach the actual charts as an appendix referenced from this table.
3. Cross-reference every signal in section 4 to its actual deviation or investigation record number; do not summarize a disposition that is not independently documented elsewhere.
4. If you integrate this report into your APR/PQR rather than issuing it standalone, state that in section 1 and reference the parent document number.
5. Confirm every regulation in the references section against the current published version before issue.